AVLN - Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs).
As of Oct 14, 2026: spot at $23.80, ATM IV 60.7%, max pain $25.00, net GEX -$1.2K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $1.05B
- Beta
- -1.13
- 52-Week Range
- 22.68-40.17
- CEO
- Lyn Baranowski
- Employees
- 55
- IPO Date
- Apr 30, 2026
- Exchange
- NASDAQ
What AVLN Looks Like to Options Traders Today
negative net gamma exposure (-$1.2K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (0.004) is roughly flat across the wings.
What This Page Covers
The AVLN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked AVLN overview questions
- What is AVLN?
- AVLN is the ticker symbol for Avalyn Pharma Inc. Common Stock, a listed security. Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. Listed on NASDAQ. AVLN is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the AVLN options snapshot look like today?
- As of Oct 14, 2026, the AVLN options snapshot shows spot at $23.80, ATM IV 60.7%, max pain $25.00, net GEX -$1.2K, expected move 17.40%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are AVLN's key statistics?
- Avalyn Pharma Inc. Common Stock (AVLN) carries a market capitalization of $1.05B, beta of -1.13 relative to the broader market, 52-week range of 22.68-40.17. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does AVLN belong to?
- Avalyn Pharma Inc. Common Stock operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare AVLN's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the AVLN data on this page?
- The options snapshot above is dated Oct 14, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, twice-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).